drugset / Trial / NCT00501709
Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
Phase 1/2
Completed
10 enrolled
University of California, San Francisco
Juvenile Diabetes Research Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
Pancreatic islets are the part of the pancreas that produce insulin and help control the blood sugar. This study aims to improve islet transplantation as a treatment for Type 1 Diabetes by using a new combination of immunosuppressive drugs that have been successful in treating other autoimmune diseases and in preventing kidney transplant rejection.
Timeline
- Start
- 2007-02
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belatacept | Protein / enzyme biologic | — | — |
| Subject | efalizumab | Monoclonal antibody | — | — |